SONN Sonnet BioTherapeutic
- 1.6500
- -0.0900-5.17%
Sonnet BioTherapeutic News
Express News | Sonnet Biotherapeutics: Clinical Benefit Seen at 4 Months Post-Initiation of Dosing in 35% of Evaluable Patients (8/23) With Advanced Solid Tumors
Express News | Sonnet Biotherapeutics: Announces Updated Clinical Data for Son-1010 as Monotherapy/Combined With Anti-Pd-L1, With Increase in Dose-Escalation Target
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined With an Anti-PD-L1, Along With an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
Express News | EF Hutton Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $7
Sonnet BioTherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 275.84% EF Hutton $11 → $7 Maintains Buy 02/15/2024 1510.74% Chardan Capital $75 → $30 Maintain
Express News | Sonnet Biotherapeutics Holdings Inc: Qtrly Shr $0.07
Sonnet BioTherapeutic | 10-Q: Quarterly report
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early safety data from the c
Sonnet BioTherapeutics Files to Sell 5M Shares of Common Stock for Holders
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be partic
Express News | Sonnet Biotherapeutics Holdings: Post Purchase Agreement, Co Has Right From Time to Time at Option to Sell to Chardan up to Lesser of $25 Mln
Express News | Sonnet Biotherapeutics Holdings: On May 2, Entered Purchase Agreement, Registration Rights Agreement, Each With Chardan for “Chef,” Chardan’s Facility
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs
RNLX, ASLN and SONN Among Pre-market Losers
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
US equities were in red territory after Monday's opening bell as traders looked ahead to the consumer inflation report due for release later in the week for clues on the direction of the Federal Reser
Top Premarket Gainers
Kidpik Corp. (PIK) shares soared more than three-fold Monday premarket following a 5.9% gain in the previous session. The L.S. Starrett Company (SCX) shares surged 56% after the company agreed to a ta
Express News | Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Express News | Sonnet BioTherapeutics Says Early Safety Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy Met Study's Initial Pre-Specified Objective
Sonnet BioTherapeutics Announces Early Safety Data From the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‐080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability
Analysis
Price Target
No Data
